Dipeptide species are accumulated in the chronic myelogenous leukemia (CML) stem cells [1]. To investigate the molecular mechanisms of the accumulation of dipeptide species in CML stem cells, we performed transcriptome sequencing of long-term stem cells, short-term stem cells, progenitor cells from healthy control and CML-affected mice (GSE70031). The transcriptome data revealed that the expres...

Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder characterized by the presence of the Philadelphia chromosome, t(9;22), which is a constitutively active tyrosine kinase that causes excessive proliferation and differentiation of myeloid cells in the bone marrow. Most patients are either asymptomatic or present with fatigue, abdominal fullness, and splenomegaly. This is ...

Chronic myelogenous leukemia (CML) is a type of leukemia originating from hematopoietic stem cells characterized by unregulated proliferation of myeloid cells. Leukemic cells carry the chromosome, a translocation between one chromosome 9 and one chromosome 22. This chromosome has the fusion gene which consists of fragments of the breakpoint cluster region (BCR) and abelson murine leukemia (ABL)...

Blood, Vol. 50, No. 1 (July), 1977 115 The specificity of an antiserum (titer 1:500) raised in a monkey against K-562 undifferentiated cells with the Philadelphia chromosome (Ph’) was determined. Antibody-dependent, complement-mediated cytotoxicity was demonstrated for both bone marrow cells and peripheral leukocytes from patients with myelogenous and lymphatic leukemias, but not for mature nor...

objective: one of the most significant damages to the genetic material is oxidative deamination of dna and free nucleotides in the cell pool. incorporation of deaminated purine nucleotides such as inosine triphosphate (itp, ditp) into the dna can increase the frequency of base substitution mutation. it has been suggested that presence and accumulation of these rough nucleotides can lead to gene...

We describe the application of fluorescence in situ hybridization (FISH) in a case of suspected chronic myelogenous leukemia (CML), cytogenetically characterized by a t(21;22) with no clear involvement of chromosome 9. The dual color FISH technique, performed using specific painting probes for chromosomes 9,21,22 and a BCR/ABL translocation probe, enabled us to confirm the diagnosis of CML by d...

Blood, Vol. 50, No. 1 (July), 1977 115 The specificity of an antiserum (titer 1:500) raised in a monkey against K-562 undifferentiated cells with the Philadelphia chromosome (Ph’) was determined. Antibody-dependent, complement-mediated cytotoxicity was demonstrated for both bone marrow cells and peripheral leukocytes from patients with myelogenous and lymphatic leukemias, but not for mature nor...

GVHD and relapse are two major causes of death after HPC transplantation.1 The most efficient method for prevention of GVHD consists of Tcell depletion of the graft.2-5 However, this usually leads to greatly increased risks of leukemia relapse,3,6,7 due to the loss of the graft-versus-leukemia (GVL) effect that has been recognized as an important component of the anti-leukemic efficacy of allog...

Chronic myelogenous leukemia (CML) is a cancer of the blood, and the immune system is known to play an important role in the dynamics of CML [5]. Similarly, it is known that immune interactions are important for HIV [6]. My collaborators and I created models for each of these diseases, including immune system dynamics. We then applied statistical and mathematical techniques to compare and predi...

Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug erupti...